Patents Assigned to IMMUTRIX THERAPEUTICS, INC.
-
Publication number: 20240100090Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.Type: ApplicationFiled: October 30, 2023Publication date: March 28, 2024Applicant: Immutrix Therapeutics, Inc.Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 11918728Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: November 6, 2020Date of Patent: March 5, 2024Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller, Jose A. Diaz-Aunon
-
Patent number: 11896753Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: March 3, 2020Date of Patent: February 13, 2024Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 11839628Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.Type: GrantFiled: March 26, 2021Date of Patent: December 12, 2023Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Publication number: 20230372596Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is in a range from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is in a range from about 0.1:100 to 100:0.1 to produce a third filtrate.Type: ApplicationFiled: August 3, 2023Publication date: November 23, 2023Applicant: Immutrix Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 11759561Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: September 1, 2020Date of Patent: September 19, 2023Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Publication number: 20220120648Abstract: Methods for quantifying an amount of exosomes in subject derived biological fluid and comparing to a control provides for a method of identifying a medical condition. Removing an amount of the exosomes by adsorption and binding of the exosomes to an absorbent material, and administering the reconstituted biological fluid comprising a reduced amount of exosomes back to the subject also provides for a method of treating the identified medical condition.Type: ApplicationFiled: October 17, 2019Publication date: April 21, 2022Applicant: IMMUTRIX THERAPEUTICS, INC.Inventors: Jose A. Diaz-Aunon, Oleta A. Sandiford, Pranela Rameshwar
-
Publication number: 20210236543Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.Type: ApplicationFiled: March 26, 2021Publication date: August 5, 2021Applicant: IMMUTRIX THERAPEUTICS, INC.Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 10960022Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.Type: GrantFiled: October 16, 2018Date of Patent: March 30, 2021Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Publication number: 20200397973Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: ApplicationFiled: September 1, 2020Publication date: December 24, 2020Applicant: ImMutriX Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 10773011Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: May 2, 2017Date of Patent: September 15, 2020Assignee: Immutrix Therapeutics, Inc.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 10617813Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: November 18, 2015Date of Patent: April 14, 2020Assignee: IMMUTRIX THERAPEUTICS, INC.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 10137151Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.Type: GrantFiled: April 17, 2015Date of Patent: November 27, 2018Assignee: IMMUTRIX THERAPEUTICS, INC.Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
-
Patent number: 9669151Abstract: A method comprising obtaining a bodily fluid from a subject; contacting the bodily fluid with an adsorbent material comprising a synthetic carbon particle (SCP) to produce a first filtrate having a level of disease mediators (y); contacting the first filtrate with an adsorbent material comprising the SCP and an anion exchange resin where the ratio of SCP to anion exchange resin is from about 0.1:100 to 100:0.1 to produce a second filtrate; contacting the second filtrate with an adsorbent material comprising the SCP and a cation exchange resin where the ratio of SCP to cation exchange resin is from about 1:100 to produce a third filtrate; and administering the third filtrate to the subject.Type: GrantFiled: March 9, 2015Date of Patent: June 6, 2017Assignee: IMMUTRIX THERAPEUTICS, INC.Inventors: Carol A. Rae, Jan Simoni, Grace Simoni, John F. Moeller